The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...

The assessment of immunogenicity in biotherapeutics is crucial to ensuring both the safety and efficacy of these advanced medicinal products. By detecting anti-drug antibodies (ADAs) and understanding ...

UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the ...

From the 1980s, therapeutic protein drugs — monoclonal antibodies, proteins, antibody-drug conjugates, bispecific antibodies, etc. — have been widely employed in the treatment of HIV, tumors and other ...

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer. Cell-Based ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

Chimeric antigen receptor (CAR) T-cell therapies hold great promise for the treatment of both hematologic cancers and solid cancers. However, they also pose unique challenges for bioanalysis. For ...

Delivering cutting-edge peer-reviewed research on using nucleic acids and related compounds to alter gene expression for therapeutic purposes. A new article in the peer-reviewed journal Nucleic Acid ...

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab ® Generic ...